A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

NCT04880109 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDIV

Sponsor class

Stopped Enrollment Challenges

Conditions

COVID-19

Interventions

DRUG: APX-115
DRUG: Placebo

Sponsor

Aptabio Therapeutics, Inc.

Collaborators

[object Object]